2012-12-03 17:50:57 -
With reference to the joint press releases by OctoPlus N.V. ("OctoPlus" or the
"Company") (Euronext: OCTO) and Dr. Reddy's Laboratories Ltd. ("Dr.
dated 22 October 2012 and 16 November 2012, OctoPlus today announces that it
calls an Extraordinary General Meeting of Shareholders pursuant to Article
2:108a of the Dutch Civil Code (Burgerlijk wetboek) and in connection with the
intended public offer by an indirect wholly owned subsidiary of Dr. Reddy's for
all the issued and outstanding shares in the capital of OctoPlus pursuant to
Article 18, paragraph 1 of the Dutch Public Takeover Decree (Besluit openbare
biedingen Wft) (the "Decree").
Extraordinary General Meeting of Shareholders to take place on 15 January 2013
An Extraordinary General Meeting of Shareholders of OctoPlus has been called to
be held on 15 January 2013,
14.00 hours CET, at OctoPlus' headquarters in
Leiden. The meeting documents are now available in the Corporate Information
section of the website www.octoplus.nl.
This press release does not constitute or form part of an offer for ordinary
shares in OctoPlus. It is an announcement that an Extraordinary General Meeting
of Shareholders of OctoPlus has been called. The information in this press
release is not intended to be complete and for further information explicit
reference is made to the offer memorandum, which is expected to be published mid
December 2012, after approval of the Dutch Authority for the Financial Markets
(Stichting Autoriteit Financiële Markten). In addition, a position statement of
the Executive Board and Supervisory Board of OctoPlus shall be made available in
accordance with Article 18, paragraph 2 and annex G of the Decree.
For further information, please contact:
For further information about OctoPlus, please contact Investor Relations:
telephone number +31 (71) 524 1064, or send an e-mail to Investor Relations at
OctoPlus is a specialty pharmaceutical company focused on the development and
manufacture of improved injectable pharmaceuticals based on our proprietary drug
delivery technologies that exhibit fewer side effects, improved patient
convenience and a better efficacy/safety balance than existing therapies.
OctoPlus also focuses on the development of long-acting, controlled release
versions of known protein therapeutics, peptides and small molecules, including
specialty generics. OctoPlus is a leading European provider of advanced drug
formulation and clinical scale manufacturing services to the pharmaceutical and
biotechnology industries, with a focus on difficult-to-formulate active
OctoPlus is listed on NYSE Euronext in Amsterdam under the symbol OCTO. For more
information about OctoPlus, please visit our website www.octoplus.nl.
This is a press release by OctoPlus pursuant to provisions of Article 5:25i of
the Dutch Act on the Financial Supervision (Wet op het financieel toezicht) and
Article 4, paragraph 3 of the Decree, in connection with the intended public
offer by an indirect wholly owned subsidiary of Dr. Reddy's for all the issued
and outstanding shares in the capital of OctoPlus.
This document may contain certain forward-looking statements relating to the
business, financial performance and results of the Company and the industry in
which it operates. These statements are based on OctoPlus N.V.'s current plans,
estimates and projections, as well as its expectations of external conditions
and events. In particular the words "expect", "anticipate",
"estimate", "project", "plan", "may",
"should", "would", "will", "intend",
"believe" and similar expressions are intended to identify forward-looking
statements. We caution investors that a number of important factors, and the
inherent risks and uncertainties that such statements involve, could cause
actual results or outcomes to differ materially from those expressed in any
forward-looking statements. In the event of any inconsistency between an English
version and a Dutch version of this document, the English version will prevail
over the Dutch version.
Click here for the press release in PDF:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: OctoPlus N.V. via Thomson Reuters ONE